ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advances in therapy, 30%-40% of pediatric acute myeloid leukemia (AML) patients still experience treatment failure due to relapse or toxicity. Current risk stratification based on genetic features remains insufficient, and epigenetic biomarkers for pediatric AML are understudied. This study aimed to evaluate the prognostic and predictive value of Methods: We enrolled 69 newly diagnosed pediatric AML patients treated with standardized chemotherapy. Promoter methylation levels were measured by multiplex methylation-specific PCR. Associations between methylation status and clinical characteristics, survival outcomes, and response to hypomethylating agents (HMAs) were analyzed using univariate and multivariate Cox regression, sensitivity analyses, and subgroup validation. Results: Methylation levels of all three genes were significantly associated with age and core binding factor abnormalities. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.